Hemogenyx Pharmaceuticals Plc

HEMO.L · LSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-£5,619-£6,691-£3,987-£5,108
Dep. & Amort.£639£646£195£126
Deferred Tax£0£0£0-£18
Stock-Based Comp.£0£0£18£153
Change in WC£603-£834£243£101
Other Non-Cash£260£773£621£2,118
Operating Cash Flow-£4,117-£6,106-£2,911-£2,627
Investing Activities
PP&E Inv.-£13-£117-£429-£818
Net Acquisitions£0£0£0£0
Inv. Purchases£0£0-£2-£139
Inv. Sales/Matur.£0£0£0£0
Other Inv. Act.-£12£85£11£18
Investing Cash Flow-£25-£32-£420-£939
Financing Activities
Debt Repay.-£635-£639-£110-£3,222
Stock Issued£3,712£5,088£0£12,000
Stock Repurch.£0£0£0£0
Dividends Paid£0£0£0£0
Other Fin. Act.£0£0£0£0
Financing Cash Flow£3,077£4,449-£110£8,778
Forex Effect-£24£403-£876-£183
Net Chg. in Cash-£1,088-£1,285-£4,308£5,029
Supplemental Information
Beg. Cash£1,248£2,533£6,841£1,812
End Cash£159£1,248£2,533£6,841
Free Cash Flow-£4,130-£6,223-£3,340-£3,445